about
The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancerThe transferrin receptor part II: targeted delivery of therapeutic agents into cancer cellsAlternative splicing of Slo channel gene programmed by estrogen, progesterone and pregnancyPropulsion of African trypanosomes is driven by bihelical waves with alternating chirality separated by kinks.Binding specificity and internalization properties of an antibody-avidin fusion protein targeting the human transferrin receptor.Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer.A versatile targeting system with lentiviral vectors bearing the biotin-adaptor peptide.A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy.An antibody recognizing the apical domain of human transferrin receptor 1 efficiently inhibits the entry of all new world hemorrhagic Fever arenaviruses.Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor.IBC's 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5-8, 2011, San Diego, CA.The transferrin receptor and the targeted delivery of therapeutic agents against cancer.Insights into the mechanism of cell death induced by saporin delivered into cancer cells by an antibody fusion protein targeting the transferrin receptor 1.Lethal iron deprivation induced by non-neutralizing antibodies targeting transferrin receptor 1 in malignant B cells.Changes in global gene expression in rat myometrium in transition from late pregnancy to parturition.Paclitaxel-loaded PCL-TPGS nanoparticles: in vitro and in vivo performance compared with Abraxane®.Enhanced cytotoxicity of an anti-transferrin receptor IgG3-avidin fusion protein in combination with gambogic acid against human malignant hematopoietic cells: functional relevance of iron, the receptor, and reactive oxygen species.A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model.Conjugation of an anti transferrin receptor IgG3-avidin fusion protein with biotinylated saporin results in significant enhancement of its cytotoxicity against malignant hematopoietic cells.Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2/neu expressing tumors.Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CATissue-specific regulation of Ca(2+) channel protein expression by sex hormones.Sub-ångström cryo-EM structure of a prion protofibril reveals a polar clasp.Antibody-mediated targeting of the transferrin receptor in cancer cells.ATP activation of plasma membrane yeast H(+)-ATPase shows complex kinetics independently of the degree of purification.Production of monoclonal antibodies in microfluidic devices.Development of image analysis software for quantification of viable cells in microchips.Phosphoryl Group Exchange between ATP and ADP Catalyzed by H+-ATPase from Oat RootsAntibody-cytokine fusion proteins: applications in cancer therapy
P50
Q28257323-BF994D8C-1A2E-4743-920A-44ABAC1252EBQ28258883-1CAD8346-C0FC-4EE2-AE8B-0987966FB65AQ28572577-4246D794-63ED-4C71-8B2F-AB1F84739682Q30491791-9EA9EC5A-CFBC-4A90-87C9-CF066A061DF1Q33299793-4FED25CF-9713-45DB-8163-D2292360924AQ33668653-7091B9F7-6BDE-4298-9AD1-6A3C233B651BQ33711477-4929241A-6D4D-4D65-8512-892AC0CBD4DEQ34675499-518AC406-3915-4D60-BC9D-1EAECE5F0398Q35826829-9F7857E4-9824-438A-843C-BCAEAE6722B0Q35849193-EA510EE4-DEDA-4A96-8FCB-8033EBC35025Q35992493-6CBAA722-2CDD-49C8-B5DF-31A874816DE5Q36406637-B6BF7931-BEA9-4395-8057-A6E4CC038EA9Q36442636-B25E7031-9AF5-4343-938F-4E90AE759C9CQ37068076-F27C592B-319A-4EA5-9F2B-B12078761F5CQ37086164-133F51E8-54D2-4E7D-9A03-6E85DD011C10Q39092697-FC7519FA-A66B-4342-8A1E-1EFDB77368FFQ39926217-DBA3C1F6-C8FF-43F4-852F-9B50743C45C5Q40001395-C15CB757-BADF-48C3-852D-7E2457FE4E4BQ40048104-83DAA933-F991-48FE-BDD8-A9DF8F5D9322Q40285535-83E5E6F5-6E29-4FFA-8DEB-69449083FFD8Q42557137-80A861B3-87B9-4F1F-BEC7-9F74D70B167FQ45712719-546BD491-8588-4A57-BE9F-743C9F0FFC6FQ48239663-1C5CA7E8-753E-463E-87A8-F0BCE7EDA0F8Q50111855-3F344A78-01D9-43F8-8DE4-2E78E377ABE9Q52386787-046FF850-031C-4F10-B75A-0199B53618D8Q52681931-1EBE6F53-1AF6-4EE6-A80D-BE352A1345D4Q55284956-7F50208B-9E2C-44A4-ABEF-FEEFCFB4FB76Q74770703-C4B51FF2-8403-4E41-8F81-BCD8E2C7E8F2Q81069451-A4694399-EF46-43E8-8055-A1FC50562F39
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Gustavo Helguera
@ast
Gustavo Helguera
@en
Gustavo Helguera
@es
Gustavo Helguera
@nl
type
label
Gustavo Helguera
@ast
Gustavo Helguera
@en
Gustavo Helguera
@es
Gustavo Helguera
@nl
altLabel
Gustavo F Helguera
@en
prefLabel
Gustavo Helguera
@ast
Gustavo Helguera
@en
Gustavo Helguera
@es
Gustavo Helguera
@nl
P106
P1153
9942486200
P21
P31
P4012
P496
0000-0003-1509-3564